GW Pharmaceuticals Shares New Data on Epidiolex at European Epilepsy Congress

GW Pharmaceuticals has presented positive data on the safety and effectiveness of Epidiolex, recently approved by the U.S. Food and Drug Administration (FDA) to treat epileptic seizures in Dravet and Lennox-Gastaut syndromes, as well as the potential mechanisms behind its anti-epileptic properties.

The data were presented at the 13th Annual European Congress of Epileptology (ECE), held recently in Vienna, Austria.

GW Pharmaceuticals’ lead cannabinoid compound, Epidiolex, received FDA-approval in June for the treatment of seizures associated with both Dravet and Lennox-Gastaut syndromes, in patients ages 2 and older. These syndromes are rare and severe forms of childhood-onset epilepsy that are very difficult to treat.

In epilepsy, the endocannabinoid system — a collection of receptors, mainly in the brain, that are configured to accept only cannabinoids — is defective and can lead to seizures. Epidiolex is a purified form of cannabidiol (CBD), the most abundant non-psychoactive cannabinoid in the marijuana plant, that mimicks the natural

... read more at: